142 related articles for article (PubMed ID: 10802504)
21. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways.
Rieux-Laucat F; Le Deist F; Fischer A
Cell Death Differ; 2003 Jan; 10(1):124-33. PubMed ID: 12655301
[TBL] [Abstract][Full Text] [Related]
22. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
[TBL] [Abstract][Full Text] [Related]
23. [The autoimmune lymphoproliferative syndrome: a disorder of programmed cell death].
Seegers D; Peña AS; Bouma G
Ned Tijdschr Geneeskd; 2004 Feb; 148(8):371-6. PubMed ID: 15032090
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome.
Tighe PJ; Stevens SE; Dempsey S; Le Deist F; Rieux-Laucat F; Edgar JD
Genes Immun; 2002 Oct; 3 Suppl 1():S66-70. PubMed ID: 12215906
[TBL] [Abstract][Full Text] [Related]
25. Impaired apoptosis of lymphocytes derived from patient with decreased expression of caspase-8 results in Alps-like phenotype.
Grzela T; Krauze A; Grzela K; Lazarczyk M; Niderla J; Brawura-Biskupski-Samaha R; Dziunycz P; Milewski L; Korczak-Kowalska G; Kulus M
Int J Mol Med; 2004 Nov; 14(5):937-42. PubMed ID: 15492869
[TBL] [Abstract][Full Text] [Related]
26. Investigation of suspected deficient Fas-mediated apoptosis in a father and son.
Hanlon MG; Gacis ML; Kakakios AM; Kilham H
Cytometry; 2001 Mar; 43(3):195-8. PubMed ID: 11170106
[TBL] [Abstract][Full Text] [Related]
27. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene.
Wei A; Cowie T
Eur J Haematol; 2007 Oct; 79(4):363-6. PubMed ID: 17725802
[TBL] [Abstract][Full Text] [Related]
28. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr.
Xie C; Patel R; Wu T; Zhu J; Henry T; Bhaskarabhatla M; Samudrala R; Tus K; Gong Y; Zhou H; Wakeland EK; Zhou XJ; Mohan C
Int Immunol; 2007 Apr; 19(4):509-22. PubMed ID: 17369192
[TBL] [Abstract][Full Text] [Related]
29. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
Fuchs H; Posovszky C; Lahr G; van der Werff ten Bosch J; Boehler T; Debatin KM
Pediatr Res; 2009 Feb; 65(2):163-8. PubMed ID: 18948840
[TBL] [Abstract][Full Text] [Related]
30. Clinical, immunological, and pathological consequences of Fas-deficient conditions.
Le Deist F; Emile JF; Rieux-Laucat F; Benkerrou M; Roberts I; Brousse N; Fischer A
Lancet; 1996 Sep; 348(9029):719-23. PubMed ID: 8806292
[TBL] [Abstract][Full Text] [Related]
31. [The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases].
Beltinger C; Böhler T; Schrappe M; Ludwig WD; Debatin KM
Klin Padiatr; 1998; 210(4):153-8. PubMed ID: 9743945
[TBL] [Abstract][Full Text] [Related]
32. Coombs' negative haemolytic anaemia as a first manifestation of autoimmune lymphoproliferative disease.
Guitton C; Le Deist F; Bader-Meunier B
Br J Haematol; 2005 May; 129(3):442-3. PubMed ID: 15842670
[No Abstract] [Full Text] [Related]
33. Childhood linear IgA disease in association with autoimmune lymphoproliferative syndrome.
Wong CS; Arkwright PD; Rieux-Laucat F; Cant AJ; Stevens RF; Judge MR
Br J Dermatol; 2004 Mar; 150(3):578-80. PubMed ID: 15030346
[TBL] [Abstract][Full Text] [Related]
34. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.
Infante AJ; Britton HA; DeNapoli T; Middelton LA; Lenardo MJ; Jackson CE; Wang J; Fleisher T; Straus SE; Puck JM
J Pediatr; 1998 Nov; 133(5):629-33. PubMed ID: 9821419
[TBL] [Abstract][Full Text] [Related]
35. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.
Straus SE; Jaffe ES; Puck JM; Dale JK; Elkon KB; Rösen-Wolff A; Peters AM; Sneller MC; Hallahan CW; Wang J; Fischer RE; Jackson CE; Lin AY; Bäumler C; Siegert E; Marx A; Vaishnaw AK; Grodzicky T; Fleisher TA; Lenardo MJ
Blood; 2001 Jul; 98(1):194-200. PubMed ID: 11418480
[TBL] [Abstract][Full Text] [Related]
36. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane.
Siegel RM; Muppidi JR; Sarker M; Lobito A; Jen M; Martin D; Straus SE; Lenardo MJ
J Cell Biol; 2004 Nov; 167(4):735-44. PubMed ID: 15557123
[TBL] [Abstract][Full Text] [Related]
37. Causes and consequences of the autoimmune lymphoproliferative syndrome.
Rao VK; Straus SE
Hematology; 2006 Feb; 11(1):15-23. PubMed ID: 16522544
[TBL] [Abstract][Full Text] [Related]
38. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome.
Schiano TD; Te HS; Thomas RM; Hussain H; Bond K; Black M
Am J Gastroenterol; 2001 Oct; 96(10):2984-91. PubMed ID: 11693337
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management.
van der Werff ten Bosch J
Paediatr Drugs; 2003; 5(3):185-93. PubMed ID: 12608883
[TBL] [Abstract][Full Text] [Related]
40. The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood.
Deutsch M; Tsopanou E; Dourakis SP
Clin Rheumatol; 2004 Feb; 23(1):43-4. PubMed ID: 14749982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
